Kiadis Pharma Revenue and Competitors

Claim your profile

Amsterdam, NH Netherlands

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kiadis Pharma's estimated annual revenue is currently $16.4M per year.(i)
  • Kiadis Pharma's estimated revenue per employee is $155,000

Employee Data

  • Kiadis Pharma has 106 Employees.(i)
  • Kiadis Pharma grew their employee count by -28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11M710%N/AN/A
#2
$1.7M2717%N/AN/A
#3
$60.3M38911%N/AN/A
#4
$16.4M106-28%N/AN/A
#5
$29.6M15314%$45.5MN/A
#6
$9.8M6343%N/AN/A
#7
$4.9M7726%N/AN/A
#8
$13M84-3%$179.8MN/A
#9
$18.8M121-15%N/AN/A
#10
$6M39-9%N/AN/A

Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.

keywords:N/A

N/A

Total Funding

106

Number of Employees

$16.4M

Revenue (est)

-28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kiadis Pharma News

2022-04-17 - Natural Killer (NK) Cell Therapeutics Market to See Generated ...

Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...

2022-04-17 - Acute Lymphocytic/Lymphoblastic Leukemia (ALL ...

... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...

2022-04-17 - Alpha Thalassemia Market Size, Share, Forecast 2022-2029 ...

Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.

2021-05-14 - KIADIS PHARMA N.V. Kiadis Pharma N : - Notice of Annual General Meeting of Shareholders

Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...

2021-05-13 - Notice of Annual General Meeting of Shareholders

Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.8M106-10%N/A
#2
$26.5M10614%N/A
#3
$15.4M106-14%N/A
#4
$22.3M1062%N/A
#5
$21.7M10638%N/A